COVID-19, Oncology
Conditions
Brief summary
This registry will allow to evaluate the correlation of the incidence and evolution of associated symptoms of infection of COVID-19 with the biological and clinical parameters in patients followed in Oncology during the COVID-19 pandemic.
Detailed description
Prior to conducting any of the screening tests, the Investigator or his designee will explain the trial fully to the prospective patient and provide him with a copy of the Patient Information Leaflet/Informed Consent Form. If the patient is willing to participate to the trial, his given oral, free, informed and express consent will be collected and traced in his medical file. The screening questionnaire will be completed. The patient's suitability for the trial will be confirmed by the inclusion/exclusion criteria . Following completion of the Baseline Questionnaire, patients will receive the Daily Questionnaire. This is designed to assess if they have developed symptoms associated with COVID-19 infection. If a participant responds that they are not feeling well, a series of follow-up questions will be asked regarding what symptoms they are currently experiencing. The Daily Questionnaire will be asked of patients every day throughout the Observation Period of 6 months. At the end of the Observation Period, all patients will complete a series of questionnaires relating to the conduct of the study and tools employed.
Interventions
OTHERObvio-19 app
As part of this research, the patient must complete questionnaires daily on the Obvio-19 application, one of 5 minutes. Evaluation of the proportion of patients with COVID-19 infection's symptoms known to be associated with COVID-19 diagnosis (fever, cough, loss of taste and smell, sore throat, muscle pain, diarrhea, fatigue, difficulty eating and drinking and shortness of breath) followed during a period of 6 months. To assess the prevalence and course of symptoms of COVID-19 infection of patients followed during a period of 6 months. To establish the correlation of the COVID-19 infection with the biological and clinical data of patients from the Oncology cohort of the Groupe hospitalier Paris Saint-Joseph in Paris followed during a period of 6 months.
Sponsors
ObvioHealth
Fondation Hôpital Saint-Joseph
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
As part of this research, the patient must complete questionnaires daily on the Obvio-19 application, one of 5 minutes.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patient over 18 years of age * Patient followed in the medical oncology department of Paris Saint-Joseph Hospital Paris in France * Patient Having regular access to smartphone and internet sufficient to support study demands * French-speaking patient * Affiliation to the social security network * Willing and able to provide given oral, free, informed and express consent
Exclusion criteria
* Patients unable or unwilling to perform all requested study tasks * Patient under tutorship or curatorship * Patient deprived of liberty * Pregnant or lactating patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| COVID-19 infection's symptoms | Observational period of 6 months | Evaluation of the proportion of patients with COVID-19 infection's symptoms known to be associated with COVID-19 diagnosis (fever, cough, loss of taste and smell, sore throat, muscle pain, diarrhea, fatigue, difficulty eating and drinking and shortness of breath) followed during a period of 6 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and course of symptoms of COVID-19 infection | During a period of 6 months | To assess the prevalence and course of symptoms of COVID-19 infection of patients followed during a period of 6 months. |
| Correlation of the COVID-19 infection with the biological and clinical data of patients | After a period of 6 months | To establish the correlation of the COVID-19 infection with the biological and clinical data of patients from the Oncology cohort of the Groupe hospitalier Paris Saint-Joseph in Paris followed during a period of 6 months. |
Countries
France
Outcome results
None listed